{
  "source": "PA-Notification-Voranigo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1457-2\nProgram Prior Authorization/Notification\nMedication Voranigo® (vorasidenib)\nP&T Approval Date 10/2024, 12/2024\nEffective Date 3/1/2025\n1. Background:\nVoranigo (vorasidenib) is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2\n(IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older\nwith Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation\nfollowing surgery including biopsy, sub-total resection, or gross total resection.\nThe National Cancer Comprehensive Network (NCCN) Drugs & Biologics Compendium also\nrecommends Voranigo for the treatment of recurrent or progressive astrocytoma and\noligodendroglioma after radiation therapy and chemotherapy as well as recurrent or progressive\nGrade 3 oligodendroglioma and recurrent or progressive Grade 3 and 4 astrocytoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Voranigo will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Astrocytoma/Oligodendroglioma\n1. Initial Authorization\na. Voranigo will be approved based on all of the following criteria:\n(1) One of the following diagnoses:\n(a) Astrocytoma\n(b) Oligodendroglioma\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Presence of IDH1 or IDH2 mutation\n-AND-\n(3) History of one of the following:\n(a) Biopsy\n(b) Sub-total resection\n(c) Gro",
    "ocytoma\n(b) Oligodendroglioma\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Presence of IDH1 or IDH2 mutation\n-AND-\n(3) History of one of the following:\n(a) Biopsy\n(b) Sub-total resection\n(c) Gross total resection\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Voranigo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Voranigo\ntherapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Voranigo [package insert]. Boston, MA: Servier Pharmaceuticals LLC; August 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed October 21, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Notification – Voranigo (vorasidenib)\nChange Control\n10/2024 New program\n12/2024 Removed Grade 2 disease requirement per NCCN Compendium.\nUpdated background and references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}